57436-38-1 Usage
Description
Octaethylene glycol di(p-toluenesulfonate), also known as Tos-PEG9-Tos, is a PEG (polyethylene glycol) linker that contains two tosyl groups. This molecule is characterized by its hydrophilic PEG spacer, which enhances its solubility in aqueous media. The tosyl group, a well-known leaving group in nucleophilic substitution reactions, is attached to both ends of the PEG chain.
Uses
Used in Pharmaceutical Industry:
Octaethylene glycol di(p-toluenesulfonate) is used as a solubility enhancer for improving the aqueous solubility of hydrophobic drugs. The hydrophilic PEG spacer increases the drug's interaction with water molecules, facilitating better dissolution and bioavailability.
Used in Chemical Synthesis:
In the field of chemical synthesis, Tos-PEG9-Tos is utilized as a versatile building block for the creation of various PEGylated compounds. The tosyl groups serve as reactive sites for nucleophilic substitution reactions, allowing for the attachment of different functional groups or molecules to the PEG chain.
Used in Bioconjugation:
Octaethylene glycol di(p-toluenesulfonate) is employed as a bioconjugation agent, enabling the covalent attachment of biomolecules, such as proteins or peptides, to the PEG chain. This process can improve the stability, solubility, and circulation time of the biomolecule in biological systems.
Used in Drug Delivery Systems:
In the development of drug delivery systems, Tos-PEG9-Tos is used as a stabilizing agent for the formation of nanoparticles or other colloidal structures. The PEG spacer provides steric stabilization, preventing aggregation and enhancing the stability of the drug delivery system in biological environments.
Used in Diagnostics:
Octaethylene glycol di(p-toluenesulfonate) can be used as a contrast agent in medical imaging techniques, such as magnetic resonance imaging (MRI) or computed tomography (CT). The PEG spacer can enhance the contrast properties of the imaging agent, improving the visualization of specific tissues or structures within the body.
Check Digit Verification of cas no
The CAS Registry Mumber 57436-38-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,4,3 and 6 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 57436-38:
(7*5)+(6*7)+(5*4)+(4*3)+(3*6)+(2*3)+(1*8)=141
141 % 10 = 1
So 57436-38-1 is a valid CAS Registry Number.
57436-38-1Relevant articles and documents
An electrochemically controlled supramolecular zip tie based on host-guest chemistry of CB[8]
Barriada, Jose L.,Domarco, Olaya,Franchi, Paola,García, Marcos D.,Lucarini, Marco,Neira, Iago,Peinador, Carlos
supporting information, p. 5228 - 5233 (2020/07/23)
Three molecular threads incorporating two viologen units attached by an oligo-ethylene glycol chain of variable length and an electron rich naphthalene moiety were prepared. The internal viologen unit is connected to the naphthalene by a rigid linker that
BIS(2-HALOACETAMIDO)-COMPOUNDS FOR USE AS LINKING AGENTS AND RESULTANT PRODUCTS WHICH COMPRISE ANTIBODIES, HALF-ANTIBODIES AND ANTIBODY FRAGMENTS
-
Page/Page column 27; 37-38, (2021/01/23)
Bis(2-haloacetamido)- compounds for use as linkers to chemically cross-linking multiple thiol groups, and particularly, although not exclusively, the thiol groups of cysteine amino acids in peptide chains are described, along with their use as linking age
SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT
-
Page/Page column 56; 57, (2017/03/08)
The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.
